These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38496519)

  • 1. Lack of TGFβ signaling competency predicts immune poor cancer conversion to immune rich and response to checkpoint blockade.
    Moore J; Gkantalis J; Guix I; Chou W; Yuen K; Lazar AA; Spitzer M; Combes AJ; Barcellos-Hoff MH
    bioRxiv; 2024 May; ():. PubMed ID: 38496519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy-induced recruitment of myeloid-derived suppressor cells abrogates efficacy of immune checkpoint blockade.
    Kwong TT; Wong CH; Zhou JY; Cheng ASL; Sung JJY; Chan AWH; Chan SL
    JHEP Rep; 2021 Apr; 3(2):100224. PubMed ID: 33604533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
    Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of Anticorrelated TGFβ Signaling and Alternative End-Joining DNA Repair Signatures that Predict Response to Genotoxic Cancer Therapy.
    Guix I; Liu Q; Pujana MA; Ha P; Piulats J; Linares I; Guedea F; Mao JH; Lazar A; Chapman J; Yom SS; Ashworth A; Barcellos-Hoff MH
    Clin Cancer Res; 2022 Apr; 28(7):1372-1382. PubMed ID: 35022323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors.
    Fu Y; Yang B; Cui Y; Hu X; Li X; Lu F; Qin T; Zhang L; Hu Z; Guo E; Fan J; Xiao R; Li W; Qin X; Hu D; Peng W; Liu J; Wang B; Mills GB; Chen G; Sun C
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37072347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer.
    Lal JC; Townsend MG; Mehta AK; Oliwa M; Miller E; Sotayo A; Cheney E; Mittendorf EA; Letai A; Guerriero JL
    Breast Cancer Res; 2021 Aug; 23(1):83. PubMed ID: 34353349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
    Isaacs J; Anders C; McArthur H; Force J
    Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leveraging big data of immune checkpoint blockade response identifies novel potential targets.
    Bareche Y; Kelly D; Abbas-Aghababazadeh F; Nakano M; Esfahani PN; Tkachuk D; Mohammad H; Samstein R; Lee CH; Morris LGT; Bedard PL; Haibe-Kains B; Stagg J
    Ann Oncol; 2022 Dec; 33(12):1304-1317. PubMed ID: 36055464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A risk score combining co-expression modules related to myeloid cells and alternative splicing associates with response to PD-1/PD-L1 blockade in non-small cell lung cancer.
    Han Y; Liu SM; Jin R; Meng W; Wu YL; Li H
    Front Immunol; 2023; 14():1178193. PubMed ID: 37492578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TUBA1C orchestrates the immunosuppressive tumor microenvironment and resistance to immune checkpoint blockade in clear cell renal cell carcinoma.
    Li J; Chen M; Tong M; Cao Q
    Front Immunol; 2024; 15():1457691. PubMed ID: 39301023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers.
    Zhu L; Liu J; Chen J; Zhou Q
    J Hematol Oncol; 2021 Dec; 14(1):206. PubMed ID: 34930377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective targeting of GARP-LTGFβ axis in the tumor microenvironment augments PD-1 blockade via enhancing CD8
    Li A; Chang Y; Song NJ; Wu X; Chung D; Riesenberg BP; Velegraki M; Giuliani GD; Das K; Okimoto T; Kwon H; Chakravarthy KB; Bolyard C; Wang Y; He K; Gatti-Mays M; Das J; Yang Y; Gewirth DT; Ma Q; Carbone D; Li Z
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36096533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. hMENA isoforms regulate cancer intrinsic type I IFN signaling and extrinsic mechanisms of resistance to immune checkpoint blockade in NSCLC.
    Trono P; Tocci A; Palermo B; Di Carlo A; D'Ambrosio L; D'Andrea D; Di Modugno F; De Nicola F; Goeman F; Corleone G; Warren S; Paolini F; Panetta M; Sperduti I; Baldari S; Visca P; Carpano S; Cappuzzo F; Russo V; Tripodo C; Zucali P; Gregorc V; Marchesi F; Nistico P
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37612043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TGFβ signaling activation correlates with immune-inflamed tumor microenvironment across human cancers and predicts response to immunotherapy.
    Xia J; Zhang Q; Luan J; Min P; Zhang H; Chen G; Ji C; Song N
    Cell Cycle; 2023 Jan; 22(1):57-72. PubMed ID: 35923142
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Klümper N; Ralser DJ; Zarbl R; Schlack K; Schrader AJ; Rehlinghaus M; Hoffmann MJ; Niegisch G; Uhlig A; Trojan L; Steinestel J; Steinestel K; Wirtz RM; Sikic D; Eckstein M; Kristiansen G; Toma M; Hölzel M; Ritter M; Strieth S; Ellinger J; Dietrich D
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance.
    Yang M; Lin C; Wang Y; Chen K; Zhang H; Li W
    Genome Med; 2022 Jul; 14(1):72. PubMed ID: 35799269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel Immune Gene-Related Prognostic Score Predicts Survival and Immunotherapy Response in Glioma.
    Luo X; Wang Q; Tang H; Chen Y; Li X; Chen J; Zhang X; Li Y; Sun J; Han S
    Medicina (Kaunas); 2022 Dec; 59(1):. PubMed ID: 36676646
    [No Abstract]   [Full Text] [Related]  

  • 18. Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy.
    Olivo Pimentel V; Marcus D; van der Wiel AM; Lieuwes NG; Biemans R; Lieverse RI; Neri D; Theys J; Yaromina A; Dubois LJ; Lambin P
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33688020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A bioinformatics-based immune-related prognostic index for lung adenocarcinoma that predicts patient response to immunotherapy and common treatments.
    Wang C; Lu T; Xu R; Chang X; Luo S; Peng B; Wang J; Yao L; Wang K; Shen Z; Zhao J; Zhang L
    J Thorac Dis; 2022 Jun; 14(6):2131-2146. PubMed ID: 35813746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment.
    Zemek RM; De Jong E; Chin WL; Schuster IS; Fear VS; Casey TH; Forbes C; Dart SJ; Leslie C; Zaitouny A; Small M; Boon L; Forrest ARR; Muiri DO; Degli-Esposti MA; Millward MJ; Nowak AK; Lassmann T; Bosco A; Lake RA; Lesterhuis WJ
    Sci Transl Med; 2019 Jul; 11(501):. PubMed ID: 31316010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.